Active Ingredient History

  • Now
Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia.   NCATS

  • Mol. Mass: 495.5345
  • ALogP: 3.07
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$0.4073 - $0.8151

United States

$0.9132 - $8.3586
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide | kad 3213 | kmd 3213 | kmd-3213 | kso-0400 | rapaflo | silodoshin | silodosin | silodyx | urief | urorec


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue